Dr. Reddy's Laboratories Ltd. announced a temporary delay in the commercial supply of its semaglutide injection due to active pharmaceutical ingredient scale-up issues [1, 2].
This disruption affects the availability of a critical medication used for weight loss and diabetes management in key markets. Because semaglutide is in high demand globally, production hurdles for generic versions can create significant gaps in patient access and affect market competition.
The company said the delay is linked to a scale-up problem with the active pharmaceutical ingredient, or API, which halted new production [1, 2]. Despite the production stoppage, the company said there is no recall risk associated with the existing supply [1, 2].
The supply disruption is expected to last until at least late October 2024 [2]. The company has flagged these issues specifically regarding its operations in India and Canada [2].
Financial markets responded to the news. Company stock fell nearly six percent [3] following the announcement of the production delay. The company has previously announced the rollout of injectable semaglutide under the brand name Obeda®, though the current API issues have complicated the commercial timeline [1].
“The supply disruption is expected to last until at least late October 2024.”
This delay highlights the technical volatility involved in scaling the production of complex peptides like semaglutide. While the lack of a recall suggests the issue is one of quantity rather than quality, the stock price dip reflects investor sensitivity to supply chain reliability in the high-growth GLP-1 medication market.
